Loading clinical trials...
Loading clinical trials...
An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
ORIC-533
Locations
8
United States
James R. Berenson, MD, Inc.
West Hollywood, California, United States
Northside Hospital Cancer Institute
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinical Rochester
Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health
Charlotte, North Carolina, United States
Start Date
January 6, 2022
Primary Completion Date
March 3, 2025
Completion Date
March 3, 2025
Last Updated
March 20, 2025
NCT07138209
NCT05913804
NCT06961669
NCT05503550
NCT05757973
NCT05011097
Lead Sponsor
ORIC Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions